http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101709085-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7dc312332a27cfd917ca38fd2399eb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c56545f4f1a25987749f2e33cd366eb7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18 |
| filingDate | 2009-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57803ce64531fd44f11739a913f3b86d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_514a609e5ef40ef420771ac30844995f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a027dcc44832bfb7ceb80d6737d503a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c0dbff989a356671e349cb68458854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0d56c18ac0830f6217b3009cbfdbcb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b1bf6347c630d19ce172f24ebfbc67a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a7cd108b22491105932f2ac3f87c327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f71be92b56c0f5e3c86dcc330b3f4d0b |
| publicationDate | 2014-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101709085-B |
| titleOfInvention | Polyethylene glycol modified human serum albumin and preparation method thereof |
| abstract | The invention relates to the biomedical technical field, in particular to polyethylene glycol modified human serum albumin and a preparation method thereof. The polyethylene glycol modified human serum albumin comprises sulfydryl of 34-bit cysteine residues on albumin molecules and N-terminal amino or free amino group combined polyethylene glycol. Modifiers adopted by the fixed-point single modification are respectively polyethylene glycol-maleimide and polyethylene glycol-propionaldehyde; modifiers adopted by the free amino group random modification are respectively polyethylene glycol-succinimide active ester or methoxy-polyethylene glycol activated by cyanuric chloride; and the modification rate of the free amino group on the albumin molecules combined with the polyethylene glycol is 3%-7%. Compared with the natural albumin, the polyethylene glycol modified human serum albumin has the excellent characteristics of prolonged half-life period, slow plasma elimination, and the like and is beneficial to reducing the medication frequency and releasing the rare albumin source. |
| priorityDate | 2009-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.